中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共3条，第1-3条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Platelet-to-Lymphocyte ratio (PLR) as a predictive marker in HER2 positive metastatic breast cancer patients treated with first-line trastuzumab therapy. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Fang, Zi-Ru;  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Shao, Xi-Ying;  Wang, Xiaojia
收藏  |  浏览/下载：45/0  |  提交时间：2022/12/23
Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Fang, Zi-Ru;  Li, Guang-Liang;  Zou, Wei-Bin;  Wang, Xiaojia;  Shao, Xi-Ying
收藏  |  浏览/下载：32/0  |  提交时间：2022/12/23
Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:  Yuan, Ying;  Fu, Xianhua;  Ying, Jieer;  Yang, Liu;  Fang, Weijia;  Han, Weidong;  Zhang, Suzhan
收藏  |  浏览/下载：49/0  |  提交时间：2022/01/10